« Return to News | Drug Sponsors

Sorrento Therapeutics acquires rights to produce rIVIG

Wednesday, January 9, 2013 02:33 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, has acquired worldwide rights that will allow for the application of its antibody library technology for the production of recombinant Intravenous immunoglobulins (rIVIG).

"With the acquisition of the proprietary rights to the rIVIG technology, we now have access to a multi-billion dollar market opportunity applying our G-MAB antibody libraries to address unmet medical needs," said Henry Ji, Ph.D., president and CEO and Sorrento.

Currently, IVIG preparations are derived from human donor blood products pooled from over 1,000 healthy individuals. However, increasing demand for IVIG products already exceeds available supply worldwide, limiting broader clinical applications. The use of Sorrento’s proprietary G-MAB library technology for the production of rIVIG may circumvent many disadvantages and obstacles currently encumbering IVIG preparations, such as potential supply constraint, costly production due to fractionation, purification and quality control challenges. Potential advantages of rIVIG include reduced batch-to-batch inconsistencies, minimal contamination risk, increased potency and no need for continued human blood donor supply.

Global sales of IVIG products exceeded $5 billion in 2012 and are projected to grow for the foreseeable future.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.